Actemra reduced the percentage of patients with Covid-19 pneumonia who progressed to requiring mechanical ventilation, but did not show an improvement in mortality, time to discharge or improvement on an ordinal scale of clinical status. Results of the Phase III COVACTA study, announced in July, were negative.
The company said that the COVACTA trial of Actemra in Covid-19 pneumonia had failed to meet its primary endpoint. Earlier this month, Regeneron and Sanofi announced that their study of a similar anti-inflammatory drug had also not met its primary endpoint.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The Phase III study of Actemra with remdesivir is expected to start enrolling toward its target of 450 patients in June, with data being reported this summer.